Cardiovascular risk in hemodialysis in Spain: Prevalence, management and target results (MAR study);Riesgo cardiovascular en hemodiálisis en España: Prevalencia, pautas de actuación y objetivos (estudio MAR)

Nefrologia

Volumn 25, Issue 3, 2005, Pages 297-306

  Portolés, José ^a   Lopez Gomez J M ^b   Aljama, P ^c   Tato, A M ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Anemia; Cardiovascular risk; Dislipidemia; Guidelines; Hemodialisis; Hipertensi n

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SMOKING; SPAIN; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; HYPERPARATHYROIDISM, SECONDARY; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SMOKING; SPAIN; UNITED STATES;

EID: 24944555861     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Amenábar JJ, García López F, Robles NR y cols.: Informe de Diálisis y Trasplante de la Sociedad Española de Nefrología y Registros Autonómicos, año 2000 Nefrología 22: 310-317, 2002.
2. USRDS: the united states renal data system. USRDS 2003 Annual Data Report. Am J Kidney Dis 42: 1-230, 2003 (S5).
3. Longenecker JC, Coresh J, Powe NR y cols.: Traditional CVD risk factors in dialysis patients compared with general population: The CHOICE study. J Am Soc Nephrol 13: 1918-1927, 2002.
4. Levin A, Djurdev O, Barrett B y cols.: Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 38: 1398-1407, 2001.
5. Mann JF, Gerstein HC, Pogue J, Bosch J, Yosuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-636, 2001.
6. Chobanian AV, Bakris GL, Black HR y cols.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2573, 2003.
7. Samak MJ, Coronado BE, Greene T y cols.: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335, 2002.
8. Levey AS, Beto JA, Coronado BE y cols.: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular disease. Am J Kidney Disease 32: 853-905, 1998.
9. Trespalacios FC, Taylor AJ, Agodoa LY, Abott KA: Incident acute coronary syndromes in chronic dialysis patients. Kidney Int 62: 1799-1805, 2002.
10. Raine AE, Margreiter R, Brunner FR y cols.: Report on management of renal failure in Europe, XXII, 1991. Nephrol DiaI Transplant 7: 7-35, 1992 (S2).
11. V. Clinical algorithms on cardiovascular risk factors in renal patients. Nephrol Dial Transplant 15: 123-154, 2000 (Supl. 5).
12. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41 (Supl. 3): S39-S58, 2003.
13. Documento de consenso 2002 sobre pautas de detección, prevención y tratamiento de la nefropatía diabética en Espana Nefrología 23: 521-530, 2002.
14. III. Clinical algorithms on renal osteodystrophy. Nephrol Dial Transplant 15 (Supl. 5): 39-57, 2000.
15. K/DOQI Clinical Practice Guidelines for Bome Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42 (Supl. 4): S52-S57, 2003.
16. European Best Practice Guidelines on anemia management. Nephrology Dialysis Transplantation 14 (Supl. 4): 1-50, 1999.
17. Portoles J, López JM, Aljama P: Morbilidad, mortalidad y anemia en pacientes en hemodiáisis (MAR 1). Nefrología 22 (suppl 4): 54, 2002.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373-383, 1987.
19. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML: A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108: 609-613, 2000.
20. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 (Supl. 1): S182-238, 2001.
21. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
22. I.NKF-KIDOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis 37 (Supl. 1): S7-S64, 2001.
23. Aljama P, Escollada R, Fernández A, Luque A y cols.: Hemodiálisis (I). En: Tratamiento Sustitutivo de la Insuficiencia Renal crónica. Guías NAC. ED: Sociedad Española de Nefrología 1996 Ediciones Harcourt España S. A. Madrid, España.
24. Naya MT, Garrido G, Cuende N, Canon J, Miranda B: Donación y trasplante renal en Espana durante 2002. Nefrología 23: 399-414, 2003.
25. Samak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35 (Supl. 1): S117-31, 2000.
26. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 (Supl. 3): S142-S156, 1998.
27. Wanner C: Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 15 (Supl. 5): 92-96, 2000.
28. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995.
29. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49: 1428-1434, 1996.
30. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 54: 1720-1725, 1998.
31. Levin A, Thompson CR, Ethier J y cols.: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134, 1999.
32. Parfrey PS: Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 15 (Supl. 5): 58-68, 2000.
33. Port FK, Hulbert-Shearon TE, Wolfe RA y cols.: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507-517, 1999.
34. Coca A: Control de tension arterial en pacientes hipertensos tratados en España. Resultados del Estudio Controlpress. Hipertensión 19: 390-399, 2002.
35. García Cortés MJ, Ceballos M: Hipertension en los pacientes en HD de la comunidad andaluza. Nefrología 24: 149-157. 2004.
36. Dorhout Mees EJ: Hypertension in haemodialysis patients: who cares? Nephrol Dial Transplant 14: 28-30, 1999.
37. Staessen JA, Gasowski J, Wang JG y cols.: Risks of untreated and treated isolated systolic hypertension in the elderly: metaanalysis of outcome trials. Lancet 355: 865-872, 2000.
38. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in "healthier" as compared with «sicker» haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplan t16: 2386-2394, 2001.
39. Pollock CA, Wyndham R, Collett PV y cols.: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 45: 897-902, 1994.
40. Portolés J, Torralbo A, Martín P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of rHuEPO in predialysis patients. Am J Kidney Dis 29: 541-548, 1997.
41. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialisis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132, 2004.
42. Pérez García R: Estudio Epidemiológico sobre el tratamiento de la anemia en España. Nefrología 23: 300-311, 2003.
43. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617, 1998.
44. Rodríguez JA, López J, Cleries M, Vela E: Vascular access for haemodialysis -an epidemiological study of the Catalan Renal Registry. Nephrol Dial Transplant 14: 1651-1657, 1999.